Skip to content
Pharma Observatory a Scientist.com platform

Condition (MeSH)

Pruritus

ClinicalTrials.gov lists 488 trials for Pruritus or a narrower condition beneath it. Novartis Pharmaceuticals has the most among industry and government lead sponsors, with 15.

MeSH D011537 Skin and Connective Tissue Diseases C17 C23
Email me this page as a PDF

Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Phase 1 Phase 1 43 Phase 1/2 Phase 1/2 10 Phase 2 Phase 2 104 Phase 2/3 Phase 2/3 10 Phase 3 Phase 3 91 Phase 4 Phase 4 37 Not applicable Not applicable 140 Observational Observational 50 Phase 1 Phase 1 43 Phase 1/2 Phase 1/2 10 Phase 2 Phase 2 104 Phase 2/3 Phase 2/3 10 Phase 3 Phase 3 91 Phase 4 Phase 4 37 Not applicable Not applicable 140 Observational Observational 50

Trials per phase

1 more section with rows

418 of the 488 trials are tagged with Pruritus itself; the rest are tagged with a narrower condition beneath it.

Get the Pruritus report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

When did Pruritus trials start? (26)

Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year. 1 trial is registered to start in 2027 or later, and not listed here.

Trials over time, by phase

  • Phase 1
  • Phase 1/2
  • Phase 2
  • Phase 2/3
  • Phase 3
  • Phase 4
  • Not applicable
  • Observational

Top of scale: 37

2000: 3 trials (Observational 1, Phase 4 1, Phase 3 1) 2002: 2 trials (Observational 1, Not applicable 1) 2003: 3 trials (Phase 4 1, Phase 3 1, Phase 2 1) 2004: 3 trials (Not applicable 1, Phase 3 1, Phase 2 1) 2005: 11 trials (Observational 1, Not applicable 4, Phase 4 1, Phase 3 3, Phase 2 1, Phase 1 1) 2006: 4 trials (Phase 4 3, Phase 2 1) 2007: 5 trials (Observational 1, Phase 4 2, Phase 3 1, Phase 1 1) 2008: 16 trials (Observational 2, Not applicable 3, Phase 3 3, Phase 2/3 1, Phase 2 4, Phase 1/2 1, Phase 1 2) 2009: 17 trials (Not applicable 3, Phase 4 3, Phase 3 2, Phase 2/3 1, Phase 2 6, Phase 1/2 1, Phase 1 1) 2010: 15 trials (Observational 1, Not applicable 3, Phase 4 1, Phase 3 3, Phase 2/3 2, Phase 2 2, Phase 1/2 1, Phase 1 2) 2011: 19 trials (Observational 2, Not applicable 3, Phase 4 1, Phase 3 11, Phase 1 2) 2012: 18 trials (Observational 1, Not applicable 2, Phase 4 2, Phase 3 5, Phase 2 3, Phase 1/2 1, Phase 1 4) 2013: 16 trials (Observational 1, Not applicable 3, Phase 3 3, Phase 2 7, Phase 1 2) 2014: 16 trials (Not applicable 3, Phase 4 2, Phase 3 4, Phase 2/3 2, Phase 2 4, Phase 1 1) 2015: 16 trials (Observational 4, Not applicable 2, Phase 4 2, Phase 3 3, Phase 2/3 2, Phase 2 3) 2016: 21 trials (Observational 2, Not applicable 3, Phase 4 1, Phase 3 3, Phase 2 8, Phase 1/2 2, Phase 1 2) 2017: 24 trials (Observational 2, Not applicable 6, Phase 4 2, Phase 3 7, Phase 2 7) 2018: 32 trials (Observational 4, Not applicable 6, Phase 4 3, Phase 3 11, Phase 2 8) 2019: 35 trials (Observational 5, Not applicable 11, Phase 3 5, Phase 2 10, Phase 1/2 1, Phase 1 3) 2020: 36 trials (Observational 3, Not applicable 15, Phase 4 1, Phase 3 3, Phase 2/3 1, Phase 2 8, Phase 1 5) 2021: 20 trials (Observational 1, Not applicable 7, Phase 4 2, Phase 3 3, Phase 2 6, Phase 1 1) 2022: 34 trials (Observational 3, Not applicable 13, Phase 4 1, Phase 3 9, Phase 2 3, Phase 1 5) 2023: 20 trials (Observational 5, Not applicable 8, Phase 4 2, Phase 2/3 1, Phase 2 2, Phase 1/2 1, Phase 1 1) 2024: 29 trials (Observational 3, Not applicable 15, Phase 4 2, Phase 3 2, Phase 2 5, Phase 1/2 1, Phase 1 1) 2025: 37 trials (Observational 5, Not applicable 17, Phase 4 2, Phase 3 3, Phase 2 5, Phase 1 5)

Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.

Trials started per year
Year Trials started
2026 (partial year) 29
2025 37
2024 29
2023 20
2022 34
2021 20
2020 36
2019 35
2018 32
2017 24

Showing 10 of 26 earlier years.

Start your 14-day trial Email me all 26 earlier years as a PDF

Forecast of the full-year count, planned starts included, not rows of this table: about 37 trials starting in 2026 and about 35 in 2027, the average of the 24 months through September, counted as registered and carried forward, with about 0.7 times the starts already registered for the rest of 2026 added. The rows of this table count trials registered so far with a start date in the year, planned starts included; the forecast looks ahead to the count for the whole year, so it is not the same measure. In backtests on conditions of this size, forecasts made part-way through the year were typically off by about 15 percent and ran about 1 percent high against the count later registered; forecasts made before the year began were off by about 26 percent and ran about 20 percent low against the count later registered. The part-way figures are from forecasts that used a multiple fitted only on earlier years. These figures rest on a few years of history (target years from 2018 to 2025, varying by figure), place each condition as it is mapped today rather than as it was then, and score against a count for the newest year that was still being revised. Only condition series were scored.

Prediction, not a registry value: median of 30 months from start to primary completion across 41 trials still running at the 2026-10-09 snapshot; registered median of 11 months across 348 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.

What phase are Pruritus trials in? (9)

Shown in this order: phase order.

Show the trials by phase as a table
Trials by phase
Phase Trials
Phase 1 43
Phase 1/2 10
Phase 2 104
Phase 2/3 10
Phase 3 91
Phase 4 37
Not applicable 140
Observational 50
Expanded access 3

How many Pruritus trials are recruiting? (10)

Shown in this order: the order a trial moves through, from not yet recruiting to unknown.

Trials by recruitment status
Status Trials
Not yet recruiting 24
Recruiting 39
Enrolling by invitation 4
Active, not recruiting 8
Available 1

Showing 5 of 10 statuses.

Start your 14-day trial Email me all 10 statuses as a PDF

Status as registered on ClinicalTrials.gov. Each trial is counted once.

Which lead sponsors run the most Pruritus trials? (10)

Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.

Lead sponsors
Sponsor Trials
Novartis Pharmaceuticals 15
Cara Therapeutics, Inc. 14
GlaxoSmithKline 12
Incyte Corporation 10
Pfizer 9

Showing 5 of 10 sponsors.

Start your 14-day trial Email me all 10 sponsors as a PDF

Which drugs are being tested for Pruritus? (6)

Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.

Drugs tested
Drug Trials
Cowhage (Mucuna Pruriens) 16
Histamine 14
CR845 14
Linerixibat 8
Serlopitant 7

Showing 5 of 6 drugs.

Start your 14-day trial Email me all 6 drugs as a PDF

Interventions as named in the registry (9)

Shown in this order: most trials first.

Interventions as named in the registry
Drug Trials
Ruxolitinib 1.5% Cream 8
Vehicle Cream 8
Secukinmab 8
Dupilumab/Dupixent 7
PO Morphine 6

Showing 5 of 9 interventions.

Start your 14-day trial Email me all 9 interventions as a PDF

These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.

Which serious adverse events do Pruritus trials report? (10)

Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.

Serious adverse events in this condition's trials
Adverse event Subjects affected Trials
Pneumonia 110 27
Sepsis 67 12
Fluid overload 55 6
Hyperkalaemia 53 5
Dyspnoea 49 11

Showing 5 of 10 adverse events.

Start your 14-day trial Email me all 10 adverse events as a PDF

Which publications cover Pruritus? (609)

Shown in this order: major-topic papers first, then newest, then most linked to trials.

Publications
Publication Journal Year Major topic
Linerixibat in patients with primary biliary cholangitis and cholestatic pruritus (GLISTEN): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial. The lancet. Gastroenterology & hepatology 2026 Yes
Efficacy, Safety and Tolerability of Volixibat, an IBAT Inhibitor, in Patients With Intrahepatic Cholestasis of Pregnancy. Liver international : official journal of the International Association for the Study of the Liver 2026 Yes
Onset and Long-Term Maintenance of Optimal Itch Response in Adult Patients with Moderate-to-Severe Atopic Dermatitis Treated with Dupilumab: Post Hoc Analysis from Two Phase 3 Trials. Advances in therapy 2025 Yes
Remibrutinib in Chronic Spontaneous Urticaria. The New England journal of medicine 2025 Yes
Efficacy and Safety of Nemolizumab in Patients With Moderate to Severe Prurigo Nodularis: The OLYMPIA 1 Randomized Clinical Phase 3 Trial. JAMA dermatology 2025 Yes

Showing 5 of 609 publications.

Start your 14-day trial Email me the first 50 publications as a PDF

Sub-conditions in MeSH (3)

MeSH descendants one level down with at least one trial, most trials first.

Not on this page

Not measured: delivery record.

Checked, with nothing recorded for this condition: prevalence and rare-disease identity.

Browse all condition evidence pages